Protein Signatures in T1D

The incidence of type 1 diabetes is rising, particularly in infants. There is evidence that this early increase is the result of an accelerated disease progression after the initiation of islet autoimmunity. Progression from islet autoimmunity to clinical diabetes is not uniform and even in subjects with multiple high-affinity islet autoantibodies a high variability in disease progression ranging from 6 months to 15 years is observed. There is a clinical need to predict and distinguish such patients at high risk of fast progression to overt T1D in order to prioritise therapeutic intervention.

Protein Signatures in T1D

In this project, we perform a LC-MSMS based quantitative proteomic approach on serum samples collected from prospectively followed children, in order to identify peptide and protein signatures correlating with high progression rates of the disease. Such potential novel biomarkers will then be quantified by selected reaction monitoring (SRM) on a large cohort of samples. Bioinformatic modelling approaches will reveal suitability of these markers for prediction of disease progression.